Relationship Between Emphysema Progression at CT and Mortality in Ever-Smokers: Results from the COPDGene and ECLIPSE Cohorts
Authors
Affiliations
Background The relationship between emphysema progression and long-term outcomes is unclear. Purpose To determine the relationship between emphysema progression at CT and mortality among participants with emphysema. Materials and Methods In a secondary analysis of two prospective observational studies, COPDGene (, NCT00608764) and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE; , NCT00292552), emphysema was measured at CT at two points by using the volume-adjusted lung density at the 15th percentile of the lung density histogram (hereafter, lung density perc15) method. The association between emphysema progression rate and all-cause mortality was analyzed by using Cox regression adjusted for ethnicity, sex, baseline age, pack-years, and lung density, baseline and change in smoking status, forced expiratory volume in 1 second, and 6-minute walk distance. In COPDGene, respiratory mortality was analyzed by using the Fine and Gray method. Results A total of 5143 participants (2613 men [51%]; mean age, 60 years ± 9 [standard deviation]) in COPDGene and 1549 participants (973 men [63%]; mean age, 62 years ± 8) in ECLIPSE were evaluated, of which 2097 (40.8%) and 1179 (76.1%) had emphysema, respectively. Baseline imaging was performed between January 2008 and December 2010 for COPDGene and January 2006 and August 2007 for ECLIPSE. Follow-up imaging was performed after 5.5 years ± 0.6 in COPDGene and 3.0 years ± 0.2 in ECLIPSE, and mortality was assessed over the ensuing 5 years in both. For every 1 g/L per year faster rate of decline in lung density perc15, all-cause mortality increased by 8% in COPDGene (hazard ratio [HR], 1.08; 95% CI: 1.01, 1.16; = .03) and 6% in ECLIPSE (HR, 1.06; 95% CI: 1.00, 1.13; = .045). In COPDGene, respiratory mortality increased by 22% (HR, 1.22; 95% CI: 1.13, 1.31; < .001) for the same increase in the rate of change in lung density perc15. Conclusion In ever-smokers with emphysema, emphysema progression at CT was associated with increased all-cause and respiratory mortality. © RSNA, 2021 See also the editorial by Lee and Park in this issue.
Ashraf Cheema A, Sharif G, Kumar S, Butt H, Khan I, Hussain J Cureus. 2024; 16(11):e73771.
PMID: 39677156 PMC: 11646560. DOI: 10.7759/cureus.73771.
Anti-CELA1 antibody KF4 prevents emphysema by inhibiting stretch-mediated remodeling.
Ojha M, Smith N, Devine A, Joshi R, Goodman E, Fan Q JCI Insight. 2024; 9(1).
PMID: 38193533 PMC: 10906462. DOI: 10.1172/jci.insight.169189.
COPD in People with HIV: Epidemiology, Pathogenesis, Management, and Prevention Strategies.
Byanova K, Abelman R, North C, Christenson S, Huang L Int J Chron Obstruct Pulmon Dis. 2023; 18:2795-2817.
PMID: 38050482 PMC: 10693779. DOI: 10.2147/COPD.S388142.
Pathogenesis and management of emphysema in people with HIV.
Kreniske J, Kaner R, Glesby M Expert Rev Respir Med. 2023; 17(10):873-887.
PMID: 37848398 PMC: 10872640. DOI: 10.1080/17476348.2023.2272702.
Quantitative Analysis for Lung Disease on Thin-Section CT.
Iwasawa T, Matsushita S, Hirayama M, Baba T, Ogura T Diagnostics (Basel). 2023; 13(18).
PMID: 37761355 PMC: 10528918. DOI: 10.3390/diagnostics13182988.